Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

mpleted. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may resul
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , ... or the "Company") (NYSE MKT: NSPR), a leader in embolic ... the Company,s President and Chief Executive Officer, and ... participate in the Benchmark Company, LLC One-on-One Investor Conference on ... Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... 2013 This market report summarizes ... profiling carried out in May 2013. The full ... of the responses for each question, its segmentation ... also highlights some interesting differences, particularly between Pharma, ... models were developed to estimate the in house ...
(Date:5/24/2013)... The Oklahoma tornado left the ... the mayor of Moore, one of the heavily damaged towns, ... report from cnn.com. Reaching out to also be of help, ... Safe Shield to counter the looming mold problem. , The ... 22, 2013, caused 24 deaths, My Cleaning Products shared. Ten ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
(Date:5/22/2013)... fatty acids in fish oil have long been thought ... American Heart Association currently recommends eating at least two ... in omega 3s. However, the mechanism behind this protective ... scientists led by Jason R. Carter of Michigan Technological ... that fish oil might specifically counteract the detrimental effects ...
(Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2
... Siberia,s Lake Baikal, the world,s largest and most biologically diverse ... result of climate change, according to an analysis by a ... lake is considered a treasure trove for biologists and was ... proportion of its rich fauna and flora are found nowhere ...
... Hopkins University School of Medicine have found that a ... plastic devices as intravenous (IV) bags and catheters can ... in the American Journal of Physiology , these ... of the common side effectsloss of taste, short term ...
... but their plant diversity is diminished. In the last ... doubled worldwide. This additional supply of plant nutrients is ... causes of biodiversity loss this century. The research, under ... of Zurich, shows for the first time the exact ...
Cached Biology News:Climate change threatens Lake Baikal's unique biota 2Chemical found in medical devices impairs heart function 2Fertilization intensifies competition for light and endangers plant diversity 2
Rabbit polyclonal to QKI...
... Mass Spectrometry Applications ,In the age ... emerged as a powerful protein identification and ... is now an important intermediate step in ... to identification of specific proteins in the ...
... ammonium sulfate are compatible with thermostable enzymes ... and AmpliThem™™ DNA polymerases. You can significantly ... one experiment by adding your own enzyme, ... supplied with the kit. This capability is ...
... MasterAmp™ PCR Optimization Kits without ammonium sulfate ... in PCR, such as Taq and AmpliThem™™ ... performance of PCR systems in one experiment ... PCR primers into the PreMixes supplied with ...
Biology Products: